PU.1 and USF Are Required for Macrophage-specific Mannose Receptor Promoter Activity*

Brian S. EganDagger , Kirk B. Lane§, and Virginia L. ShepherdDagger parallel **

From the Departments of Dagger  Biochemistry, § Pathology, and  Medicine, Vanderbilt University and the parallel  Department of Veterans Affairs Medical Center, Nashville, Tennessee 37212

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the current study we report the isolation of 854 base pairs of the rat mannose receptor promoter. Analysis of the sequence revealed one Sp1 site, three PU.1 sites, and a potential TATA box (TTTAAA) 33 base pairs 5' of the transcriptional start site. The tissue specificity of the promoter was determined using transient transfections. The promoter was most active in the mature macrophage cell line NR8383 although the promoter also showed activity in the monocytic cell line RAW. No activity was observed in pre-monocytic cell lines or epithelial cell lines. Mutation of the TTTAAA sequence to TTGGAA resulted in a 50% decrease in activity in transient transfection assays suggesting that the promoter contains a functional TATA box. Using electrophoretic mobility shift assays and mutagenesis we established that the transcription factors Sp1, PU.1, and USF bound to the mannose receptor promoter, but only PU.1 and USF contributed to activation. Transient transfections using a dominant negative construct of USF resulted in a 50% decrease in mannose receptor promoter activity, further establishing the role of USF in activating the rat mannose receptor promoter. Comparison of the rat, mouse, and human sequence demonstrated that some binding sites are not conserved. Gel shifts were performed to investigate differences in protein binding between species. USF bound to the rat and human promoter but not to the mouse promoter, suggesting that different mechanisms are involved in regulation of mannose receptor expression in these species. From these results we conclude that, similar to other myeloid promoters, transcription of the rat mannose receptor is regulated by binding of PU.1 and a ubiquitous factor at an adjacent site. However, unlike other myeloid promoters, we have identified USF as the ubiquitous factor, and demonstrated that the promoter contains a functional TATA box.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The maturation of phagocytes during the latter stages of myeloid cell differentiation is accompanied by the appearance of a number of myeloid-restricted proteins. One of these proteins, the mannose receptor, is absent from monocytes but is expressed on mature macrophages, appearing very late in the differentiation process (1, 2). The mannose receptor is a 175-kDa type I transmembrane protein and is a member of the C-type lectin family (3). The protein has been purified from a variety of species (4, 5), and the murine and human cDNA sequences have been reported (6, 7). Several in vivo functions have been proposed for the macrophage mannose receptor: endocytosis of extracellular peroxidases and hydrolases during the resolution phase of inflammation (8), phagocytosis of unopsonized pathogens (9), and antigen capture for eventual presentation to T cells (10).

Studies in our laboratory for the past several years have focused on the mechanisms involved in regulation of expression of the mannose receptor in macrophages. Mannose receptor expression is a marker of the mature macrophage, although expression has also been reported on dendritic cells (11) and retinal pigmented epithelial cells (12). Mannose receptor protein is absent in freshly isolated monocytes and appears during in vitro differentiation in the presence of colony-stimulating factors (13). Recent studies from a number of laboratories have begun to shed some light on the mechanisms that regulate myeloid-restricted gene expression. Studies of the promoters of these genes have revealed a number of potential factors that modulate myeloid-specific gene expression, and a pattern of features required for activation of these genes during myeloid differentiation has emerged (14, 15). Control of tissue specificity typically resides in approximately 150 bp1 5' of the major transcriptional start site. All of the myeloid promoters contain consensus binding sites for PU.1, a member of the ets family of transcription factors (16). A role for this factor in myeloid cell differentiation has been supported by the findings that macrophage development is restricted in PU.1 null mice, and that PU.1 expression is up-regulated during commitment of multipotential stem cells to the myeloid lineage (17). The activity of a number of myeloid promoters requires an intact PU.1 site (18-26), and the PU.1 sites are in close proximity to a site that binds a second transcription factor. Binding elements for four of these factors have been identified to date: AML1, a member of the Runt/PEBP2/CBF family; C/EBPalpha or C/EBPbeta ; Sp1; and AP-1 (14). Binding of both PU.1 and this second factor are involved in controlling maximal activity. In addition, the promoters for many of these myeloid-restricted proteins lack a TATA box and have multiple transcriptional start sites.

Some information on factors involved in mannose receptor regulation has come from the recent reports of the isolation and partial characterization of the promoters for the human and murine mannose receptor genes (27, 28). Potential regulatory mechanisms were identified in the murine sequence, and myeloid restricted activity was demonstrated for the human promoter. Both promoters contain PU.1 sites, and one of these sites appears to be involved in murine promoter activity. Using transient transfection of mannose receptor-negative myeloid cells, Eichbaum et al. (28) reported that activity of the murine promoter required binding of PU.1 and Sp1 at sites within the first 200 bp. What has hampered further studies on a complete description of factors involved in mannose receptor transcriptional regulation is the inability to efficiently transfect primary macrophages. We have recently described mannose receptor expression in a rat alveolar macrophage cell line (29), and in the current study we have used this cell line to examine potential factors involved in mannose receptor transcriptional regulation.

Studies of the control of mannose receptor expression are important for two reasons: first, the mannose receptor is a key phagocytic receptor involved in first-line host defense against a variety of invading pathogens, including Mycobacterium tuberculosis (30), Candida albicans (31), Pseudomonas aeruginosa (32), and Pneumocystis carinii (33). Second, the mannose receptor is expressed only on the mature macrophage (1, 2) making this a unique model system to study the mechanisms involved in monocyte to macrophage maturation. In the current study we report the isolation of 854 bp of the rat mannose receptor promoter and investigate the elements within this fragment that contribute to mannose receptor expression in mature macrophages. We have focused on sites that are potentially involved in myeloid-restricted expression of the rat mannose receptor, and have extended the findings from both the human and murine systems to include regulation and function of the mannose receptor promoter in a mannose receptor-positive macrophage cell line.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- NR8383 cells were obtained from Dr. R. Helmke (University of Texas Health Science Center) and maintained in Ham's F-12 medium with 15% fetal bovine serum (Life Technologies, Inc.). The murine macrophage cell line RAW264, the human monocytic line HL60, and the human epithelial line A549 were obtained from the American Type Tissue Culture Collection (ATCC, Rockville, MD). RAW and HL60 cells were maintained in RPMI 1640 with 10% fetal bovine serum and antibiotics. A549 epithelial cells were maintained in F-12K supplemented with 10% fetal bovine serum and antibiotics. Rat bone marrow-derived macrophages were prepared from Sprague-Dawley rats as described previously (34) by culture for 5-7 days in the presence of L cell-conditioned medium. Rat bone marrow macrophages were maintained following differentiation in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.

Promoter Isolation-- The strategy for isolation of the rat mannose receptor promoter was a modification of the procedure used for cloning the human mannose receptor promoter (27) as follows: a synthetic oligonucleotide of known sequence (Integrated DNA Technologies) was ligated to the ends of rat genomic DNA pieces generated by digestion with HincII. This oligonucleotide formed an "anchor" sequence to which a complementary primer could be hybridized as primer 1 for generation of mannose receptor promoter fragments by PCR using a mannose receptor-specific oligonucleotide as primer 2. The digests contained genomic DNA (1 µg), in a buffer containing 10 mM ATP and 10 mM dithiothreitol. Double-stranded, dephosphorylated synthetic oligonucleotide and T4 DNA ligase were added to the DNA plus restriction enzyme mixture, and incubated overnight at 37 °C. These conditions favored the direction of complete digestion of the DNA at the respective restriction endonuclease sites, with a synthetic oligonucleotide ligated onto each blunt end. Any genomic DNA that re-ligated would again be cut by the restriction enzyme. At the completion of the overnight incubation, a PCR reaction was set up by addition of a mannose receptor-specific 3' primer derived from the partial rat cDNA sequence obtained in our laboratory (5'-CCAAAGAATACTGCCCAAGTCCCCGG-3') and a single-stranded oligonucleotide complementary to the synthetic oligonucleotide (5'-TCCAGGCCAGGGAAATTGGAGCACAGG-3') using the Expand Long Template PCR system (Boehringer Mannheim). The reaction mixture was incubated at 95 °C for 2 min, followed by 30 cycles of 92 °C for 20 s and 68 °C for 5 min. This procedure yielded a fragment of approximately 2.2 kilobases. This fragment was further digested with BglII/SpeI resulting in a fragment of approximately 900 bp. This fragment was subcloned into pGEM-T (Promega) and sequenced using vector-based primers.

Primer Extension-- An oligonucleotide derived from the rat mannose receptor cDNA corresponding to positions +23 to +46 (5'-CCGGGTTGCCCCTTGGCTTAGTCC-3') was 5'-end labeled with [gamma -32P]ATP and T4 polynucleotide kinase (Promega). A primer with the 5'-end at the predicted +1 position of the mannose receptor mRNA (5'-AGTCAGACGGCTCCCAGACC-3') was used as a control to verify that no extension would occur from this site. Total RNA was isolated from rat bone marrow macrophages using TriReagent (Molecular Research Center, Inc) according to the manufacturer's instructions. Labeled primer and 5 µg of RNA were incubated in Tris-HCl, pH 8.3, containing 0.15 M KCl and 1 mM EDTA for 90 min at 65 °C. Extension of the primer was initiated by addition of avian myeloblastosis virus reverse transcriptase in Tris-HCl buffer, pH 8.3, with 5.5 mM dithiothreitol, 10 mM MgCl2, actinomycin D (7 µg), and 150 µM dNTP mixture. This mixture was incubated at 42 °C for 1 h, then terminated by addition of salmon sperm DNA and RNase A. Nucleic acid was then extracted with phenol/chloroform/isoamyl alcohol and precipitated with ethanol. The resulting pellet was collected by centrifugation and analyzed on a 9% polyacrylamide, 7 M urea sequencing gel.

Plasmid Constructs-- The 854-bp mannose receptor promoter was cloned into the pGL2 basic vector (Promega) containing the luciferase cDNA after BglII/SspI digestion (MR854). The proximal 656-bp promoter fragment (MR656) was generated by HindIII digestion of the 854-bp promoter with subsequent ligation into a HindIII-digested pGL2 vector. A construct containing the proximal 228 bp of the mannose receptor promoter (MR228) was generated by digestion of the 854-bp construct with SmaI and PvuII, followed by re-ligation. The -108 (MR108) and -48 (MR48) constructs were generated by PCR using the MR656 as a template, the appropriate sense primers, and a vector-based antisense primer. The products were digested with HindIII, and ligated into the pGL2 basic vector at the HindIII/SmaI site. Mutations in the mannose receptor promoter were introduced using a PCR-based approach as described by Ho et al. (35). Complimentary sense and antisense primers containing the desired mutations were obtained from Integrated DNA Technologies (Coralville, IA). The products of the PCR reactions containing the mutations were isolated, digested with the appropriate restriction enzymes, and ligated into MR854 following removal of the specific mutated region. The dominant negative USF1 expression vector, Delta bTDU1, was a kind gift from Dr. Raymondjean (Institut Cochin de Genetique Moleculaire).

Transfection and Reporter Gene Assays-- Electroporation was used for transfection of the cells lines under the following conditions: mannose receptor promoter-luciferase DNA (5 µg) and CMV-Renilla-luciferase (pRL-CMV, Promega) (1 µg) were added to 250 µl of serum-free media. RAW cells were transfected at a concentration of 107 cells/reaction at 280 V and 960 µfarads. NR8383 cells were transfected at a concentration of 5 × 106 cells/reaction at 250 V and 960 µfarads. A549 cells (5 × 106) were transfected at 250 V and 960 µfarads. NR8383 and HL60 cells were also transfected using DEAE-dextran as follows: cells were washed with phosphate-buffered saline, then resuspended in trypsin/EDTA for 3 min at room temperature. The cells were collected by centrifugation, and suspended in 1 ml of 25 mM Tris, pH 7.4, containing 0.14 M NaCl, 5 mM KCl, and 0.7 mM K2HPO4. DNA (10 µg) and 50 µl of 4 mg/ml DEAE-dextran were added, and the mixture incubated at room temperature for 20 min. The transfected cells were then plated into 100-mm tissue culture dishes for 24 h in the media used for routine culture. Firefly and Renilla luciferase activities were measured using the dual luciferase reporter assay system (Promega) according to the manufacturer's instructions. The pGL2-basic vector (Promega) was used as a negative control in transfection assays. The pRL-CMV vector was used to correct for transfection efficiency. Data are expressed as the luciferase activity for each sample normalized to the Renilla luciferase activity.

Electrophoretic Mobility Shift Assays (EMSA)-- Nuclear extract was isolated from cell preparations as follows: 107 cells were suspended in 300 µl of lysis buffer A (10 mM HEPES, pH 7.9, containing 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.4% Nonidet P-40, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 5 µg/ml leupeptin, and 500 ng/ml pepstatin), and placed on ice for 10 min. After centrifugation for 1 min at 14,000 rpm, the pellet containing the nuclei was washed once with buffer A, then suspended in 200 µl of buffer B (20 mM HEPES, pH 7.9, with 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, plus levels of protease inhibitors as in A) and vortexed for 15 min. Cell debris was removed by centrifugation and nuclear protein was quantified using the Bio-Rad Protein Assay (Bio-Rad).

Single-stranded oligonucleotides (Integrated DNA Technologies) were annealed and 5' nucleotides were added using Klenow (Promega). The resulting double-stranded oligonucleotides were end-labeled using T4 polynucleotide kinase (Promega) and [gamma -32P]ATP (NEN Life Science Products Inc.). Labeled oligonucleotide (2 × 105 cpm), single-stranded nonspecific DNA (200 ng), nuclear extract (10 µg), and binding buffer (3 µl) (20 mM Tris-HCl, pH 7.5, with 20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl, 0.25 mg/ml poly(dI-dC)) were incubated at room temperature for 20 min in a total reaction volume of 15 µl. A 200-fold excess of unlabeled double-stranded oligonucleotide was used in competition assays. For supershift analysis, 2 µg of anti-USF1, anti-USF2, anti-Sp1, or anti-PU.1 antibodies (Santa Cruz) were added immediately after the addition of labeled probe. Samples were electrophoresed in a 5% polyacrylamide nondenaturing gel in 0.5 × TBE at 150 volts. The gels were dried and bands visualized by autoradiography. Sequences of double-stranded oligonucleotide probes used for the gel shifts analyses are listed in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Double-stranded oligonucleotides used for gel shift analyses


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of the Rat Mannose Receptor Transcriptional Start Site-- Primer extension analysis using rat bone marrow macrophage RNA was performed using a probe derived from the rat cDNA to determine the transcriptional start site of the rat mannose receptor gene. As shown in Fig. 1, a major extended product of 46 bp was found, with minor products of 52 and 58 bp upstream of the 5'-end of the probe. The start site of -1 indicated in Fig. 2 for the rat mannose receptor is based on the 46-bp extension product, and numbering of all oligonucleotides and positions of consensus sequences used in the current paper refer to this start site. The determined rat start site is 23 bp 5' of the start site reported by Taylor et al. (7) for the human mannose receptor and by Harris et al. (6) for the murine mannose receptor, and 21 bp 3' of the start site reported by Rouleux et al. (27) for the human mannose receptor gene. The reasons for these discrepancies are not known, although multiple start sites have been reported for other myeloid-restricted transcripts (14).


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   Identification of the transcriptional start site in the rat mannose receptor gene by primer extension. Total RNA was prepared from rat bone marrow macrophages, then incubated with an end-labeled oligonucleotide derived from the rat mannose receptor cDNA spanning the region from +23 to +46 bp (5'-CCGGGTTGCCCCTTGGCTTAGTCC-3'). The DNA was extended using avian myeloblastosis virus reverse transcriptase, then analyzed on a 9% polyacrylamide sequencing gel. Lanes 3 and 4 show the products of the extension reaction. Lanes 1 and 2 show that no extension occurred using a primer with the sequence 5'-AGTCAGACGGCTCCCAGACC-3' which was designed with the 3'-end at the predicted start site. A sequencing ladder is shown on the left for size identification of the products. The site labeled 46 is the major product, with minor products indicated at 52 and 58 bp.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 2.   Sequence of the 854-bp promoter region of the rat mannose receptor gene. The mannose receptor promoter region was isolated using PCR amplification of rat genomic DNA. The DNA was subcloned in pGEM-T and sequenced using vector-based primers. Consensus sites for PU.1 and Sp1, and a consensus E box motif are highlighted by the boxed areas. A potential TATA box is underlined.

Isolation and Characterization of the Rat Mannose Receptor Promoter Sequence-- The rat mannose receptor 5'-flanking region was isolated using a PCR-based method similar to that reported for the isolation of the human mannose receptor promoter (27). The resulting 854-bp fragment was cloned into pGEM-T and sequenced (Fig. 2). Southern analysis of rat genomic DNA using probes derived from the promoter sequence, and PCR using primers from both promoter and rat cDNA sequence confirmed that this fragment was the 5'-flanking region of the rat mannose receptor (data not shown). A comparison of the first 250 bp of the rat promoter sequence to both the human and murine mannose receptor promoter sequences is shown in Fig. 3. There is almost complete identity of murine and rat sequences over the first 150 bp, with a homology over the entire 250 bp of 87%. There is lower homology between the rodent sequences and the human, with very little agreement upstream of position -150. The homology of rat to human over the 250-bp sequence is 56%. The highest degree of homology among the three sequences occurs between -30 and -150, suggesting that important regulatory sites may be located within this region. Careful analysis of the first 250 bp of the rat sequence revealed a potential TATA box at -33, a core Sp1-binding site (CCGCCC) at position -91, and three potential PU.1-binding sites in the non-coding strand at -18 (GAGGAA), -106 (CAGGAA), and -163 (GAGGAA) which are conserved in the mouse and human sequences.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Comparison of the proximal 250 bp of the rat, murine, and human mannose receptor promoters. Sequences of the mannose receptors promoters from rat, mouse, and human are shown with identical residues marked by the dots. PU.1, Sp1, and E box motifs in each sequence are in bold. The human sequence is from Rouleux et al. (27), and the murine sequence is from Eichbaum et al. (28).

Analysis of Rat Mannose Receptor Promoter Activity in Mannose Receptor-positive and Mannose Receptor-negative Macrophages and Non-myeloid Cells-- To determine if the 854-bp 5'-region of the rat mannose receptor gene directs cell-specific expression, promoter activity was determined in mannose receptor-positive macrophages, mannose receptor-negative macrophages, and mannose receptor-negative non-macrophage cell lines using a reporter gene assay. In Fig. 4A, NR8383 macrophages (open bars) and A549 epithelial cells (solid bars) were transfected with the pGL2-MR854, -MR656, -MR228, -MR108, -MR48, and promoterless pGL2 basic vectors. PU.1 sites are represented by the closed ovals, and the Sp1 sites by the open ovals. Cells were co-transfected with pRL-CMV as an internal control for transfection efficiency. The 228-bp fragment was almost as active as the 854-bp promoter in NR8383 cells, suggesting that this region contains the necessary myeloid-specific sites as suggested by Clarke and Gordon (14) for myeloid-restricted gene expression. Interestingly, there was a slight decrease in activity with the MR656 construct. This supports the observation by Rouleux et al. (27) that the region from -250 to -750 may contain a repressor site that is overcome by the additional 5' bases in MR854. In addition, Eichbaum et al. (28) reported that sequences 5' of -200 bp in the murine promoter reduced activity. The MR108 construct showed approximately 50% of the activity of MR228. MR108 still contains two PU.1 sites and the Sp1 site, but maximal activity may require the upstream PU.1 site at -163. MR48 still exhibited some activity in NR8383 cells when compared with basic vector alone, suggesting that the one remaining PU.1 site (-18 bp) also contributes to macrophage-specific expression from this promoter. Mannose receptor promoter activity in A549 cells (Fig. 4A) and Hep2 cells (data not shown) was comparable to levels observed when these cells were transfected with empty vector, supporting the conclusion that the mannose receptor promoter is active only in myeloid cell types.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4.   Transient transfection assays of mannose receptor promoter-luciferase truncated constructs. The 854-bp mannose receptor promoter construct (MR854) was cloned into the pGL2 basic vector. Truncated fragments were produced from this construct by restriction digest and each was subcloned into the pGL2 vector. Cells were transfected with 5 µg of mannose receptor promoter-pGL2, and 1 µg of CMV-Renilla-luciferase to control for transfection efficiency. DNA was introduced by electroporation (NR8383, RAW, and A549 cells) or DEAE-dextran (HL60 cells) using the conditions described under "Experimental Procedures." Cells were then plated in complete medium in 100-mm tissue culture dishes for 24 h prior to assaying luciferase activity. Panel A shows a comparison of the relative light units for firefly luciferase normalized to Renilla luciferase for each mannose receptor construct in both NR8383 macrophages and A549 epithelial cells. Data are the average of duplicate determinations and are representative of four separate experiments (MR854, MR656, and MR228) or two separate experiments (MR108 and MR48). Panel B shows the relative activity for the MR854 construct in NR8383 macrophages, RAW264 monocytes, and HL60 myeloid cells. Data are the average of triplicate determinations ± S.D. and are representative of three separate experiments.

In Fig. 4B activity of the MR854 construct is compared in cell lines representative of various stages of myelopoiesis. NR8383 cells express mannose receptor and are representative of mature macrophages, RAW cells are monocyte-like and do not express mannose receptor, and HL60 cells are pre-monocytic cells that also do not express mannose receptor. Activity in NR8383 cells was 5-fold greater than activity in RAW cells, while the construct was completely inactive in HL60 cells. These results suggest that mannose receptor promoter activity is maximally active in mature mannose receptor-positive macrophages, shows less activity in monocytes, and is inactive in pre-monocytic cells.

The Mannose Receptor Promoter Contains a Functional TATA Box-- Based on the position of the start site in the rat gene, a potential TATA box (TTTAAAA) was identified at -33 bp. Rouleux et al. (27) suggested that the sequence at -27 in the human sequence (-48 in the rat sequence) of TAAATT might be a potential TATA box, while Eichbaum et al. (28) reported that the murine promoter was TATA-less. To determine if the sequence at -33 bp in the rat promoter is a functional TATA box, we prepared mannose receptor promoter-luciferase constructs with the TTTAAA sequence mutated to TTGGAA or changed to a consensus TATA sequence (TATAAA). NR8383 cells were transiently transfected with the wild type MR854 or mutated constructs. As shown in Fig. 5, insertion of the TATAAA sequence increased activity by 25% compared with the activity of the wild type sequence (TTTAAA). However, activity of the TTGGAA mutant was reduced by approximately 50%, suggesting that the proposed TATA box (TTTAAA) in the rat mannose receptor promoter is functional but not essential. It has been suggested that a characteristic of myeloid-restricted promoters is the absence of a TATA box (14). However, neutrophil elastase (36) and proteinase-3 (26) promoters contain the sequence TATAA, and the CD14 promoter has a potential TATA box (CATAAA) -30 bp upstream of the start site (37). A recent study by Hoopes et al. (38) examined the binding of TATA-binding protein to a variety of potential TATA-box sequences. They classified the sequences CATAAA (CD14) and TTTAAA (mannose receptor) as intermediate TATA boxes compared with the strong TATAAA sequence. The observation that mutation of the TTTAAA sequence in the rat mannose receptor promoter reduced promoter activity by 50% (Fig. 5) suggests that this sequence may bind TATA-binding protein with an intermediate affinity to enhance transcription. In addition, the demonstration that this site plays a role in promoter activity supports the major transcriptional start site identified by primer extension analyses. Since this TTTAAA sequence is conserved across rat, mouse, and human, the major start site in the mouse and human promoters may be the same as in the rat promoter, and the TTTAAA sequence may function as a TATA box in these promoters.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 5.   Transient transfection assays of mannose receptor-promoter-luciferase constructs containing the wild type, consensus, and mutated TATA box sequences. The 854-bp mannose receptor promoter construct (MR854) was cloned into the pGL2 basic vector. Mutations were introduced into this construct using a PCR-based method. Cells were transfected with 5 µg of mannose receptor promoter-pGL2 and 1 µg of CMV-Renilla-luciferase to control for transfection efficiency. DNA was introduced by electroporation using the conditions described under "Experimental Procedures." Cells were then plated in complete medium in 100-mm tissue culture dishes for 24 h prior to assay of luciferase activities. Results are expressed as the relative light units for firefly luciferase normalized to Renilla luciferase. Data are the average ± S.D. of triplicate determinations, and are representative of two separate experiments. *, p < 0.05 for TTGGAA compared with TTTAAA.

Characterization of Binding of Transcription Factors to the Rat Mannose Receptor Promoter by EMSA-- Based on the above observations, we chose to examine more closely the region within the 228-bp fragment that contains conserved sequences known to bind transcription factors involved in myeloid-restricted expression of other genes (14, 15), and that contains sites conserved in the rat, human, and murine mannose receptor promoters. A double-stranded oligonucleotide was prepared spanning the region from -108 to -71 (108/71). This region contains a consensus PU.1 site (CAGGAA) on the non-coding strand (PU106), and a core Sp1 site (CCGCCC) on the coding strand (Sp91). To assess which sites in the rat mannose receptor promoter are potentially functional, we performed EMSAs using nuclear extracts from mannose receptor-positive NR8383 cells. In the experiments shown in Fig. 6, nuclear extract from NR8383 cells was incubated with labeled oligonucleotides and competitors as indicated. Labeled 108/71 oligonucleotide was bound by three major proteins from nuclear extracts as shown in lane 1. The top band was identified as Sp1 by competition with a consensus Sp1 oligonucleotide (lane 2), and by partial supershift using an Sp1 antibody (lane 3). The bottom band was identified as PU.1 by competition with a consensus PU.1 oligonucleotide (lane 4) and a supershift of the complex with anti-PU.1 antibody (lane 5). Competition with an oligonucleotide mutated at the Sp1 site (CCGCCC right-arrow CCGAGC) (S91M) reduced PU.1 but not Sp1 binding (lane 6), and competition with an oligonucleotide mutated at the PU.1 site (CAGGAA right-arrow CACCAA) (P106M) inhibited the binding of Sp1 but not PU.1 (lane 7). A labeled oligonucleotide mutated at the PU.1 site (P106M) did not bind PU.1 (lane 8) and a labeled Sp1 mutant (S91M) did not bind Sp1 (lane 9). These results demonstrate that both PU.1 and Sp1 bind to the rat mannose receptor promoter, and suggest that these two factors may play a role in the regulation of mannose receptor promoter activity.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Electrophoretic mobility shift assays. Nuclear extracts were prepared from NR8383 cells as described under "Experimental Procedures," and incubated with end-labeled double-stranded probes as indicated in Panel B. Probe 108/71 spans the -108 to -71 region of the rat mannose receptor promoter; probe 106M has a mutated PU.1 site (CC residues at -103 and -102 mutated to GG); probe 91M has a mutated Sp1 site (CC residues at -87 and -86 changed to AG). Single-stranded oligonucleotide probes were annealed and end-labeled. The labeled probes (2 × 105 cpm) were then incubated with single-stranded nonspecific DNA (200 ng), and nuclear extract (10 µg) in a total volume of 15 µl in Tris buffer with EDTA, dithiothreitol, and poly(dI-dC) for 20 min at room temperature. Samples were electrophoresed in a 5% polyacrylamide nondenaturing gel. The gels were dried and bands were visualized by autoradiography. Sequences of competitor oligonucleotides are listed in Table I. Panel A, positions of Sp1 and PU.1 are indicated. The arrow marks the position of the supershifted antibody-protein-DNA complex. The asterisk marks the position of a prominent band seen in all gel shift using the labeled 108/71 probe. Lanes 1-7 are reactions containing labeled 108/71 probe plus nuclear extract with the following additions: lane 1, buffer; lane 2, excess unlabeled Sp1 consensus oligonucleotide (Table I); lane 3, anti-Sp1 antibody; lane 4, excess unlabeled PU.1 consensus oligonucleotide (Table I); lane 5, anti-PU.1 antibody; lane 6, excess unlabeled S91M oligonucleotide; lane 7, excess unlabeled P106M oligonucleotide. Lanes 8 and 9 are nuclear extract plus labeled P106M oligonucleotide or S91M oligonucleotide, respectively.

A prominent band that migrated slightly faster than the Sp1 complex was seen in all gels (Fig. 6, lane 1). Several oligonucleotides were used as competitors in order to determine the sequence to which the unidentified factor was binding. First, two truncated oligonucleotides were made spanning the regions from -108 to -82 (108/82) and -96 to -71 (96/71). As shown in Fig. 7, competition with the 96/71 oligonucleotide completely inhibited binding of this factor to labeled 108/71 (lane 2), while competition using the 108/82 fragment did not compete with the unknown factor (lane 3), narrowing the region for binding to -82 to -71. A potential ets site exists in this sequence between -74 and -71 (GGAT) (39). The addition of a cold 108/71 oligonucleotide with 75GG74 mutated to 75CC74 was still capable of competing for the unknown factor (lane 4), thus ruling out the possibility that this protein was binding the potential ets site. Based on the above competitions we determined that the third factor was binding somewhere in the sequence CATGTGACA (-83 to -74). This stretch contains a sequence (CATGTG) that fits the core hexamer sequence CANNTG (E box) that is bound by the basic helix loop helix transcription factor family (40). Competition using the CATGTG sequence (U83, lane 5) showed conclusively that the third factor was indeed binding the E box. A number of different transcription factors are capable of binding the E box including TFE3, TFEB, TFEC, USF, Max, Myc, Mad, and Mxi (41-48). Wang and Sul (49) have shown that USF is capable of binding the specific sequence CATGTG which is present in the mannose receptor promoter (49). We therefore chose to examine the binding of USF to the 108/71 sequence using antibodies against both isoforms, USF1 and USF2, in EMSAs. In Fig. 7, lane 6, the USF1 antibody completely supershifted the unknown protein. Lane 7 shows that antibody to USF2 partially shifted the unknown protein. These results suggest that USF1 homodimers and USF1/USF2 heterdimers may be the active forms that bind to the mannose receptor promoter at the CATGTG sequence.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 7.   Electrophoretic mobility shift analysis for identification of USF binding. Gel shift assays were run as described in the legend to Fig. 6. The labeled probe used for all lanes was 108/71. The positions of the Sp1, PU.1, and USF bands are noted. The arrows mark the position of the anti-USF·USF·DNA complexes. Oligonucleotides used as competitors in lanes 2-5 are shown in Table I and Panel B. Each reaction contained the labeled 108/71 oligonucleotide plus nuclear extract with the following additions: lane 1, buffer; lane 2, excess unlabeled probe spanning -96 to 71; lane 3, excess unlabeled probe spanning -108 to -82; lane 4, excess unlabeled E74M oligonucleotide; lane 5, excess unlabeled E box consensus oligonucleotide (U83; Table I). Lanes 6 and 7 contain antibodies against USF1 (lane 6) and USF2 (lane 7).

Functional Effects of PU.1, Sp1, and USF Binding on Mannose Receptor Promoter Activity-- To assess the functional importance of binding of PU.1, Sp1, and USF to the mannose receptor promoter, the following mutations were inserted in MR854: PU163 (161CC to 161GG), PU106 (104CC to 104GG), Sp91 (87CC to 87AG), and U83 (80TG to 80CC). The effects of these mutations on MR854 promoter activity in transfection assays using NR8383 cells are shown in Fig. 8. Mutation of the PU.1 site at -106 or the E box at -83 resulted in an approximately 80% reduction in mannose receptor promoter activity. Mutation of the Sp1 site had only a slight effect on promoter activity, while mutation in the PU163 site reduced mannose receptor activity by approximately 25%. Since Sp1 had been found to function in activation of the mouse promoter, we examined the possibility that the Sp1 and PU.1 sites in the rat promoter acted cooperatively. However, mutation at both the Sp1 site and the PU106 site showed no additional decrease in promoter activity compared with the single PU106 mutation. These data suggest that the PU.1 site at -106 and the E box at -83 are critical for rat mannose receptor promoter activity.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 8.   Transient transfection assays to determine the contribution of the PU.1, Sp1, and USF sites to mannose receptor promoter activity. NR8383 cells were transfected with full-length 854 mannose receptor-luciferase constructs in pGL2, or with constructs containing site mutations in the PU.1-106 site (second bar), the Sp1-91 site (third bar), the PU.1-106 and Sp1-91 sites (fourth bar), the PU.1 site at -163 (fifth bar), or the USF site at -83 (sixth bar). Relative light units were normalized to the activity of the co-transfected CMV-Renilla-luciferase construct. DNA was introduced as described in the legend to Fig. 4 and under "Experimental Procedures." Results are expressed as the percent of activity of the MR854 construct as 100% and are representative of four separate experiments. Error bars are the S.D. of triplicate or quadruplicate determinations. *, p < .05 for the second, fourth, fifth, and sixth bars compared with control (first bar).

To further establish the role of USF in regulating mannose receptor promoter activity we used a dominant negative USF1 expression construct (Delta bTDU1) in transient transfections of NR8383 cells. The Delta bTDU1 is an expression vector encoding a USF1 protein lacking the basic region which is essential for DNA binding (50). This protein retains the helix loop helix and leucine-zipper domains and can still dimerize with both USF1 and USF2 thus serving as a dominant negative of both factors. As shown in Fig. 9, MR854 promoter activity is reduced by 50% when co-transfected with the Delta bTDU1 construct. This does not seem to be a general effect since the activity of the internal control (pRL-CMV) was nearly equal in the presence or absence of the dominant negative (data not shown).


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of a dominant negative USF on MR854 promoter-reporter expression. NR8383 cells were transfected by electroporation as described in the legend to Fig. 4 and under "Experimental Procedures" with 5 µg of mannose receptor promoter-pGL2, 1 µg of CMV-Renilla-luciferase, and 4 µg of pGL2 basic vector (open bar), or 5 µg of mannose receptor promoter-pGL2, 1 µg of CMV-Renilla-luciferase, and 4 µg of the Delta bTDU1 vector (hatched bar). Activity is expressed in relative light units (RLU) for firefly luciferase normalized to Renilla luciferase. Data are the average of triplicate determinations ± S.D., and are representative of two separate experiments. p = 0.0002 for comparison of MR854 (open bar) to MR854+Delta bTDU1 (hatched bar).

Species-specific Differences between the Rat, Mouse, and Human Mannose Receptor Promoters-- Comparison of the results of the gel shift assays and transfection experiments presented in this study to the results from the murine mannose receptor promoter study reported by Eichbaum et al. (28) reveals some significant differences. First, activity of the murine mannose receptor promoter was found to involve two PU.1 sites at -164 and -177 (-150 and -163 in the rat sequence). The murine PU164 site bound PU.1 in gel shifts, and mutation of the core sequence reduced activity in transfection assays by 50%. This binding site is not conserved in either the rat or human sequences, suggesting that this site may not be critical for mannose receptor promoter activity. No binding of PU.1 to the P177 site (-163 in the rat) was reported in the murine study, but mutation of the core sequence reduced promoter activity to basal levels. Mutation of this site in the rat promoter reduced activity by only 25%. This site is also conserved in the human mannose receptor sequence, but the role of this site in the human promoter has not yet been examined. More interestingly, murine mannose receptor promoter activity appeared to require Sp1 binding. However, in our study, mutation of the Sp1 site had no effect on mannose receptor promoter activity in mannose receptor-positive cells, either by itself or in conjunction with a mutation of the PU.1-106 site. The Sp1 core-binding site is not completely conserved in the human sequence and Sp1 does not appear to contribute to activation of the rat promoter, suggesting that other sites in the rat and human promoters may be more important for maximal activity. This theory is supported by the presence of an E box at -83 in the rat and human sequence. In order to determine if sequence differences in the -108/-71 region result in differences in protein binding between species, we performed EMSAs using species-specific oligonucleotides. Fig. 10 shows, as demonstrated above, that PU.1, Sp1, and USF bind the -108/-71 rat sequence (lane 1). In contrast only PU.1 and Sp1 bind to the mouse sequence. As we anticipated, the mouse promoter does not bind USF. The human sequence (lane 3) also binds all three factors although the G to A change in the Sp1 binding element results in a decrease in the intensity of the Sp1 band. Our conclusions from these experiments are that the PU.1 site at -106 is required for rat promoter activity, and that PU.1 acts together with the USF at -83 to regulate rat mannose receptor gene expression. In contrast, since USF does not bind to the mouse promoter, Sp1 may substitute as an activator in this species.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 10.   Comparison of protein binding to the -108/-71 region of the rat, mouse, and human mannose receptor promoters. EMSAs were run using the labeled probes spanning the region from -108 to -71 in the rat (R), mouse (M), or human (H) promoter sequence as shown in Fig. 3 plus nuclear extracts from NR8383 cells as described in the legend to Fig. 6 and under "Experimental Procedures." Positions of the SP1-, USF-, and PU.1·DNA complexes are noted in the figure.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The process of maturation of macrophages is controlled by a complex array of factors that are turned on sequentially as cells move from the bone marrow into tissues. Considerable work in the past decade has contributed significantly to our understanding of the factors that are involved as cells move through the maturation process to fully differentiated macrophages. The mannose receptor is expressed only on the end product of this differentiation cascade, the mature tissue macrophage, and thus is an excellent model gene to study the factors that control the transition from monocyte to mature macrophage. In the present study we report the isolation and characterization of the promoter region of the rat mannose receptor gene, and describe factors that are involved in regulating expression of this gene in mannose receptor-positive macrophages.

The rat mannose receptor 5'-flanking region contains multiple consensus sequences for the myeloid-specific PU.1 transcription factor. In addition, a potential binding site for the ubiquitous factor Sp1 is located just 3' of PU.1-106. The presence of a second site bound by a ubiquitous factor is characteristic of myeloid-restricted expression. We examined the role of these sites in mannose receptor promoter activity by transient transfection assays using mannose receptor promoter-luciferase constructs and by gel shift assays. We focused our studies on the region from -108 to -71 that contains binding sites for PU.1 and Sp1. The PU.1 site is conserved in the rat, murine, and human mannose receptor promoters, while the Sp1 site is completely conserved in both rat and mouse sequences (27, 28). In addition, these sites are located within the first 108 bp of the mannose receptor promoter and are in close proximity to each other. All of these features have been suggested to be important for control of myeloid-restricted expression (14).

In gel shift assays using the labeled 108/71 oligonucleotide, we observed both Sp1 and PU.1 binding (Fig. 6, lane 1). These factors were competed by excess unlabeled consensus oligonucleotides and the protein-DNA complexes were supershifted with the appropriate antibodies. PU.1 binding was not seen in extracts from non-myeloid cells such as A549, Rat II, or HeLa cells (data not shown), while Sp1 binding was observed in all cells examined, supporting the reported expression patterns of these factors (51, 52).

PU.1 is a member of the ets family of transcription factors (16). PU.1 binding has been reported to be required for activity of a number of other myeloid promoters including the promoters for growth factor receptors (18, 19), integrins (20, 21), Fc receptors (22, 23), the scavenger receptor (24), myeloperoxidase (25), and human proteinase-3 (26). The rat mannose receptor promoter contains three PU.1 sites within the first 163 bases 5' of the transcriptional start site. We examined the function of two of these sites by transfection assays using site-directed and truncated mutants of the MR854 construct. Mutation of the PU.1-106 site reduced promoter activity by approximately 80% of MR854, while mutating the PU.1 site at -163 resulted in a 25% decrease. Deletion of the 5' 622 bp resulting in MR228 had little effect on promoter activity compared with MR854. This region contains the three PU.1 sites, and appears to contain all of the required sequences for maximal activity of the mannose receptor promoter. Removal of an additional 124 5' bp (MR108) which includes one PU.1 site reduced activity by approximately 50%. Removal of the region containing the PU.1-106 site (MR48) further reduced activity to 25% of MR854. The MR48 construct retained myeloid activity and showed no activity in non-myeloid cells. These results suggest that all three PU.1 sites contribute to the control of myeloid-specific transcription driven by the mannose receptor promoter.

One characteristic feature of most myeloid promoters studied to date is the cooperation between the PU.1 site and another factor bound to a nearby site (14). Sp1 has been found to function as this second factor in a number of myeloid-specific promoters including the tyrosine kinase tec (53), CD11b (54), and c-fes (55). Sp1 was shown to be important in the mouse mannose receptor promoter, although the distance between the identified functional PU.1 site (at -163 in the rat sequence numbering) and the Sp1 site is significantly greater than is typical for myeloid promoters. It is possible that in the murine promoter the -106 PU.1 site is active in regulating promoter activity and cooperates with Sp1 binding at -91 to produce maximal activity, although this has not been tested. We examined the role of Sp1 binding in the regulation of rat mannose receptor promoter activity by transfection of MR854 with a mutation in the Sp1 binding sequence. Surprisingly, mutations within this site showed only a slight decrease (10%) in mannose receptor promoter activity and a mutation in the Sp1 site did not further decrease the reduced activity of the PU.1-106 mutant, suggesting that Sp1 does not play a role in the regulation of rat mannose receptor promoter activity. It is possible that this difference between the rat and murine studies is due to the longer promoter used for our studies or the use of mannose receptor-positive macrophages. However, another possible explanation is that an additional factor is functional in the rat mannose receptor promoter as discussed below.

Binding of a third protein to the 108/71 oligonucleotide was detected in our gel shift analyses. Through competition using portions of the 108/71 oligonucleotide, protein binding was localized to the E box (CATGTG) between positions -84 to -79. Mutation of the -80TG-79 to CC resulted in an oligonucleotide that did not bind this factor (data not shown), suggesting that these two bases are required for binding. The identity of this factor as the upstream stimulatory factor (USF) was confirmed by use of specific anti-USF1 and anti-USF2 antibodies to supershift the USF·DNA complex. In transient transfection assays, mutation of the TG residues resulted in loss of approximately 80% of promoter activity, and expression of a dominant negative USF decreased mannose receptor promoter activity by 50%, suggesting that USF binding is required for a functional rat mannose receptor promoter.

USF belongs to the family of basic helix loop helix transcription factors (40). Although these factors are ubiquitously expressed, an increasing number of studies have appeared in the past several years demonstrating a role for USF in the regulation of tissue-specific genes. USF binding has been shown to be required for human immunodeficiency virus type-1 enhancer activity in T cells (56) and for regulation of expression of the surfactant protein-A gene (57). Involvement of USF in myeloid cell differentiation was suggested by Kreider et al. (58) and Suzow and Friedman (25) reported that deletion of the E box in the myeloperoxidase gene reduced promoter activity by 5-fold. It is not yet known how USF might contribute to myeloid-specific control. In a recent study Feinman et al. (23) reported that USF bound to an E box region in the Fcgamma RIII promoter and that binding of both USF and PU.1 were required for promoter activity. The PU.1 and USF proteins interacted to form a high affinity DNA-binding complex that appeared to be responsible for the myeloid specific activity. These authors further speculated that myeloid specificity resulted from post-translational modifications of either or both factors. This is supported by the finding that phosphorylation of Sp1 and PU.1 are increased as myeloid cells differentiate (52, 59). A second mechanism suggested by Sieweke et al. (56) suggests that ets-1 and USF-1 interact to form a complex, resulting in exposure of the respective DNA-binding domains of each factor. According to both of these models a ternary complex would exist that should be detectable by EMSA. We did not detect such a complex in our assays, although the possibility remains that under the specific conditions of our assay this complex was not detectable. A third model recently proposed by Rigaud et al. (60) might explain the mutually exclusive binding that we observed in gel shift assays with the rat mannose receptor promoter probe. In this model the tissue-specific factor PU.1 binds transiently to the promoter and induces a conformational change in the chromatin which in turn exposes the binding element of a ubiquitous factor, in this case USF.

Studies of myeloid promoters, including the mannose receptor promoter, have shown that a variety of ubiquitous factors such as Sp1 and USF interact with the myeloid-specific factor PU.1 to control transcription, suggesting that these ubiquitous factors share a common function. In support of this hypothesis, Pugh and Tjian (61) have proposed that Sp1 is involved in the assembly of the basal initiation factors, particularly through interactions with TFIID. The role of Sp1 in pre-initiation complex formation has been demonstrated on both TATA-containing and TATA-less promoters (62). Similar experiments have shown that USF can function in the same manner, through interactions with TFIID (63). This interaction appears to mediate the binding of TFIID to the promoter, even in the absence of a functional TATA box. A comparison of binding elements in the rat, human, and murine mannose receptor promoter sequences shows complete conservation of the core Sp1 site in mouse and rat while the USF site is present only in the rat and human sequence. Furthermore, the Sp1 and USF sites are nearly overlapping suggesting that the function of these factors is position-dependent. The fact that the ubiquitous factor Sp1 is critical for mouse mannose receptor promoter activity while USF is required for rat promoter activity suggests that these two factors may be performing the same function in the two different species: namely, recruitment and stabilization of the pre-initiation complex.

In the present study we have demonstrated that maximal tissue specific activity is contained within the proximal 228 base pairs of the rat mannose receptor promoter. This region contains three PU.1 sites and a functional USF site. We propose that all three PU.1 sites are required for maximal expression. Mutation of PU.1-106 has the most marked effect, decreasing activity by approximately 80%. Mutation of the E box, which binds the ubiquitous factor USF, also decreases activity by approximately 80% while the expression of a dominant negative USF decreases activity by 50%. This finding is surprising in light of a recent study on the murine mannose receptor promoter which demonstrated a requirement for the ubiquitous factor Sp1. We demonstrate by EMSA that protein binding to the promoters of the rat, mouse, and human mannose receptor promoters are indeed different, with the most obvious difference being the absence of USF binding to the mouse promoter. We speculate that USF and Sp1 provide an essential and overlapping function that is required for activation from these promoters. Further studies will be required to determine the role that these transcription factors play in the different species.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants HL55977 (to V. L. S.) and EY02853 (to Dr. B. McLaughlin, University of Louisville School of Medicine).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF121966.

** To whom correspondence should be addressed: Dept. of Veterans Affairs Medical Center/Research Service; 1310 24th Ave. South, Nashville, TN 37212. Tel.: 615-327-4751 (ext: 5499); Fax: 615-321-6305; E-mail: virginia.l.shepherd{at}vanderbilt.edu.

    ABBREVIATIONS

The abbreviations used are: bp, base pair(s); CMV, cytomegalovirus; MR, mannose receptor; USF, upstream stimulatory factor; EMSA, electrophoretic mobility shift assays; PCR, polymerase chain reaction.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Shepherd, V. L., Campbell, E. J., Senior, R. M., and Stahl, P. D. (1982) J. Reticuloendothel. Soc. 32, 423-431[Medline] [Order article via Infotrieve]
  2. Rouleux-Bonnin, F., Monsigny, M., and Legrand, A. (1995) Biochem. Biophys. Res. Commun. 217, 106-112[CrossRef][Medline] [Order article via Infotrieve]
  3. Drickamer, K., and Taylor, M. E. (1993) Annu. Rev. Cell Biol. 9, 237-264[CrossRef]
  4. Stephenson, J. D., and Shepherd, V. L. (1987) Biochem. Biophys. Res. Commun. 148, 883-887[CrossRef][Medline] [Order article via Infotrieve]
  5. Blum, J. S., Stahl, P. D., Diaz, R., and Fiani, M. L. (1991) Carbohydr. Res. 213, 145-153[CrossRef][Medline] [Order article via Infotrieve]
  6. Harris, N., Super, M., Rits, M., Chang, G., and Ezekowitz, R. A. B. (1992) Blood 80, 2363-2373[Abstract]
  7. Taylor, M. E., Conary, J. T., Lennartz, M. R., Stahl, P. D., and Drickamer, K. (1990) J. Biol. Chem. 265, 12156-12162[Abstract/Free Full Text]
  8. Shepherd, V. L., and Hoidal, J. (1990) Am. J. Respir. Cell Mol. Biol. 2, 335-340[Medline] [Order article via Infotrieve]
  9. Stahl, P. D., and Ezekowitz, R. A. (1998) Curr. Opin. Immunol. 10, 50-55[CrossRef][Medline] [Order article via Infotrieve]
  10. Prigozy, T. I., Sieling, P. A., Clemens, D., Stewart, P. L., Behar, S. M., Porcelli, S. A., Brenner, M. B., Modlin, R. L., and Kronenberg, M. (1997) Immunity 6, 187-197[Medline] [Order article via Infotrieve]
  11. Longoni, D., Piemonti, L., Bernasconi, S., Mantovani, A., and Allavena, P. (1998) Int. J. Clin. Lab. Res. 28, 162-169[CrossRef][Medline] [Order article via Infotrieve]
  12. Shepherd, V. L., Tarnowski, B., and McLaughlin, B. J. (1991) Invest. Ophthamol. & Visual Sci. 32, 1779-1784[Abstract]
  13. Konish, M., Shepherd, V. L., Holt, G., and Stahl, P. D. (1983) Methods Enzymol. 98, 301-304[Medline] [Order article via Infotrieve]
  14. Clarke, S., and Gordon, S. (1998) J. Leukocyte Biol. 63, 153-168[Abstract]
  15. Valledor, A. F., Borras, F. E., Cullell-Young, M., and Celada, A. (1998) J. Leukocyte Biol. 63, 405-417[Abstract]
  16. Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., and Maki, R. A. (1990) Cell 61, 113-121[Medline] [Order article via Infotrieve]
  17. Anderson, K. L., Smith, K. A., Conners, K., McKercher, S. R., Maki, R. A., and Torbett, B. E. (1998) Blood 91, 3702-3710[Abstract/Free Full Text]
  18. Zhang, D. E., Hetherington, C. J., Chen, H. M., and Tenen, D. G. (1994) Mol. Cell. Biol. 14, 373-381[Abstract]
  19. Smith, L. T., Hohaus, S., Gonzales, D. A., Dziennis, S. E., and Tenen, D. G. (1996) Blood 88, 1234-1242[Abstract/Free Full Text]
  20. Pahl, H. L., Scheibe, R., Zhang, D., Chen, H. M., Galson, D. L., Maki, R. A., and Tenen, D. G. (1993) J. Biol. Chem. 268, 5014-5021[Abstract/Free Full Text]
  21. Rosmarin, A. G., Capri, D., Levy, R., and Simkevich, C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 801-806[Abstract]
  22. Ford, A. M., Bennett, C. A., Healy, L. E., Towatari, M., Greaves, M. F., and Enver, T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10838-10843[Abstract/Free Full Text]
  23. Feinman, R., Qiu, W. Q., Pearse, R. N., Nikolajczyk, B. S., Sen, R., Sheffery, M., and Ravetch, J. V. (1994) EMBO J. 13, 3852-3860[Abstract]
  24. Horvai, A., Palinski, W., Wu, H., Moulton, K. S., Kalla, K., and Glass, C. K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5391-5395[Abstract]
  25. Suzow, J., and Friedman, A. D. (1993) Mol. Cell. Biol. 13, 2141-2151[Abstract]
  26. Sturrock, A., Franklin, K. F., and Hoidal, J. R. (1996) J. Biol. Chem. 271, 32392-39402[Abstract/Free Full Text]
  27. Rouleux, F., Monsigny, M., and Legrand, A. (1994) Exp. Cell Res. 214, 113-119[CrossRef][Medline] [Order article via Infotrieve]
  28. Eichbaum, Q., Heney, D., Raveh, D., Chung, M., Davidson, M., Epstein, J., and Ezekowitz, R. A. B. (1997) Blood 90, 4135-4143[Abstract/Free Full Text]
  29. Lane, K. B., Egan, B., Vick, S., and Shepherd, V. L. (1998) J. Leukocyte Biol. 64, 345-350[Abstract]
  30. Schlesinger, L. (1993) J. Immunol. 150, 2920-2930[Abstract/Free Full Text]
  31. Marodi, L., Korchak, H. M., and Johnston, R. B., Jr. (1991) J. Immunol. 146, 2783-2789[Abstract/Free Full Text]
  32. Speert, D. P., Wright, S. D., Silverstein, S. C., and Mah, B. (1988) J. Clin. Invest. 82, 872-879[Medline] [Order article via Infotrieve]
  33. Ezekowitz, R. A. B., Williams, D. J., Koziel, H., Armstrong, M. Y. K., Warner, A., Richards, F. F., and Rose, R. M. (1991) Nature 351, 155-158[CrossRef][Medline] [Order article via Infotrieve]
  34. Shepherd, V. L., Konish, M. G., and Stahl, P. (1985) J. Biol. Chem. 260, 160-164[Abstract/Free Full Text]
  35. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. D., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59[CrossRef][Medline] [Order article via Infotrieve]
  36. Oelgeschlager, M., Nuchprayoon, I., Luscher, B., and Friedman, A. D. (1996) Mol. Cell. Biol. 16, 4717-4725[Abstract]
  37. Zhang, D.-E., Hetherington, C. J., Tan, S., Dziennis, S. E., Gonzalez, D. A., Chen, H.-M., and Tenen, D. G. (1994) J. Biol. Chem. 269, 11425-11434[Abstract/Free Full Text]
  38. Hoopes, B. C., LeBlanc, J. F., and Hawley, D. K. (1998) J. Mol. Biol. 277, 1015-1031[CrossRef][Medline] [Order article via Infotrieve]
  39. Karim, M. J., Urness, L. K., Thummel, C. S., Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., Maki, R. A., Gunther, C. V., Nye, J. A., and Graves, B. J. (1990) Genes Dev. 4, 1451-1460[CrossRef][Medline] [Order article via Infotrieve]
  40. Roy, A. L., Meisterernst, M., Pognonec, P., and Roeder, R. G. (1991) Nature 354, 245-248[CrossRef][Medline] [Order article via Infotrieve]
  41. Beckmann, H., Su, L., and Kadesch, T. (1990) Genes Dev. 4, 167-179[Abstract]
  42. Fisher, D. E., Carr, C. S., Parent, L. A., and Sharp, P. A. (1991) Genes Dev. 5, 2342-2352[Abstract]
  43. Zhao, G. Q., Zhao, Q., Zhou, X., Mattei, M. G., and De Crombrugghe, B. (1993) Mol. Cell. Biol. 13, 4504-4512
  44. Gregor, P., Sawadogo, M., and Roeder, R. (1990) Genes Dev. 4, 1730-1739[Abstract]
  45. Blackwood, E. M., and Eisenman, R. N. (1991) Science 251, 1211-1217[Medline] [Order article via Infotrieve]
  46. Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N., and Weintraub, H. (1990) Science 250, 1149-1151[Medline] [Order article via Infotrieve]
  47. Ayer, D. E., Kretzner, L., and Eisenman, R. N. (1993) Cell 72, 211-222[Medline] [Order article via Infotrieve]
  48. Zervos, A. S., Gyuris, J., and Brent, R. (1993) Cell 72, 223-232[Medline] [Order article via Infotrieve]
  49. Wang, D., and Sul, H. S. (1997) J. Biol. Chem. 272, 26367-26374[Abstract/Free Full Text]
  50. Lefrançois-Martinez, A., Martinez, A., Antoine, B., Raymondjean, M., and Kahn, A. (1995) J. Biol. Chem. 270, 2640-2643[Abstract/Free Full Text]
  51. Hromas, R., Orazi, A., Neiman, R. S., Maki, R., Van Beveran, C., Moore, J., and Klemsz, M. (1993) Blood 82, 2998-3004[Abstract]
  52. Saffer, J. D., Jackson, S. P., and Annarella, M. B. (1991) Mol. Cell. Biol. 11, 2189-2199[Medline] [Order article via Infotrieve]
  53. Honda, H., Ozawa, K., Yazaki, Y., and Hirai, H. (1997) Biochem. Biophys. Res. Commun. 234, 376-381[CrossRef][Medline] [Order article via Infotrieve]
  54. Chen, H. M., Pahl, H. L., Scheibe, J., Zhang, D. E., and Tenen, D. G. (1993) J. Biol. Chem. 268, 8230-8239[Abstract/Free Full Text]
  55. Heydmann, A., Juang, G., Hennessy, K., Parmacek, M. S., and Simon, M. C. (1996) Mol. Cell. Biol. 16, 1676-1686[Abstract]
  56. Sieweke, M. H., Tekotte, H., Jarosch, U., and Graf, T. (1998) EMBO J. 17, 1728-1739[Abstract/Free Full Text]
  57. Gao, E., Wang, Y., Alcorn, J. L., and Mendelson, C. R. (1997) J. Biol. Chem. 272, 23398-23406[Abstract/Free Full Text]
  58. Kreider, B. L., Benezra, R., Rovera, G., and Kadesch, T. (1992) Science 255, 1700-1702[Medline] [Order article via Infotrieve]
  59. Pongubala, J. M., VanBeveren, C., Nagulapalli, S., Klemsz, M. J., McKercher, S. R., Maki, R. A., and Atchison, M. L. (1993) Science 259, 1622-1625[Medline] [Order article via Infotrieve]
  60. Rigaud, G., Roux, J., Pictet, R., and Grange, T. (1991) Cell 67, 977-986[Medline] [Order article via Infotrieve]
  61. Pugh, B. F., and Tjian, R. (1991) Genes Dev. 5, 1935-1945[Abstract]
  62. Smale, S. T., Schmid, M. C., Berk, A. J., and Baltimore, D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4509-4513[Abstract]
  63. Bungert, J., Koker, I., During, F., and Seifart, K. H. (1992) J. Mol. Biol. 223, 885-898[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.